LOX and chromosome-type aberration frequency: Compared to animals with CsA nephropathy that were treated with the vehicle control, those treated with pan-LOX and LOXL2 inhibitors showed significant reductions in the protein expression of α-SMA (P < 0.05, Fig. 3A), suggesting reduced myofibroblast activation.